Giles Campion

About

Giles is an expert in translational medicine, and a highly experienced biotech and pharmaceutical professional across all therapeutic areas, most recently in orphan neuromuscular disorders. He has held senior global R&D roles in large pharmaceutical, diagnostics, and biotech companies, including responsibility at Board level. He served as Chief Medical Officer and Senior Vice-President of R&D at Prosensa from 2009 to 201 6, during which time the company signed a collaborative agreement with GSK worth up to $680 million with double digit royalties on product sales and co-commercialisation rights in certain territories. Prosensa went on to list on NASDAQ in 2013, raising $89.7 million in an offering nine times oversubscribed, and was eventually acquired by Biomarin in 2015 for $680 million.

Most recently, he served as Chief Medical Officer for Albumedix, Advisor to Myotherix, and a co-founder of PepGen, all companies focusing on therapies for rare diseases. At Albumedix his remit was to build a development portfolio based on the company's recombinant albumin platform and his work was instrumental in product development and an eventual financial exit for the owners of the company. Giles holds a medical degree and doctorate from Bristol University and is Board certified in Rheumatology.